Kleszcz, R.; FrÄ…ckowiak, M.; Dorna, D.; Paluszczak, J.
Combinations of PRI-724 Wnt/β-Catenin Pathway Inhibitor with Vismodegib, Erlotinib, or HS-173 Synergistically Inhibit Head and Neck Squamous Cancer Cells. Int. J. Mol. Sci. 2023, 24, 10448.
https://doi.org/10.3390/ijms241310448
AMA Style
Kleszcz R, FrÄ…ckowiak M, Dorna D, Paluszczak J.
Combinations of PRI-724 Wnt/β-Catenin Pathway Inhibitor with Vismodegib, Erlotinib, or HS-173 Synergistically Inhibit Head and Neck Squamous Cancer Cells. International Journal of Molecular Sciences. 2023; 24(13):10448.
https://doi.org/10.3390/ijms241310448
Chicago/Turabian Style
Kleszcz, Robert, Mikołaj Frąckowiak, Dawid Dorna, and Jarosław Paluszczak.
2023. "Combinations of PRI-724 Wnt/β-Catenin Pathway Inhibitor with Vismodegib, Erlotinib, or HS-173 Synergistically Inhibit Head and Neck Squamous Cancer Cells" International Journal of Molecular Sciences 24, no. 13: 10448.
https://doi.org/10.3390/ijms241310448
APA Style
Kleszcz, R., FrÄ…ckowiak, M., Dorna, D., & Paluszczak, J.
(2023). Combinations of PRI-724 Wnt/β-Catenin Pathway Inhibitor with Vismodegib, Erlotinib, or HS-173 Synergistically Inhibit Head and Neck Squamous Cancer Cells. International Journal of Molecular Sciences, 24(13), 10448.
https://doi.org/10.3390/ijms241310448